Zentalis Pharmaceuticals, Inc. - common stock (ZNTL) earnings
ZNTL earnings moved a median of 0.00% by the close. Quarterly and annual ZNTL reports and results, each read against the price at its own news timestamp. Back to the ZNTL overview →
20 measured ZNTL earnings events.
Where these ZNTL earnings landedvs 20 measured ZNTL earnings reactions
| Middle 50% of ZNTL earnings reactions | -5.40% to +3.13% |
|---|---|
| Median reaction (to close) | 0.00% |
| Measured reactions | 20 |
Point-in-time · zero look-ahead
Half of the 20 ZNTL earnings events with a measured close landed between -5.40% and +3.13%; 45% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Zentalis Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | +2.03% | -9.83% | |
| Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates | Press release | +2.03% | -9.83% | |
| Form 10-Q Zentalis Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | +1.69% | +3.13% | |
| Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress | Press release | +1.69% | +3.13% | |
| Form 10-K Zentalis Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | -1.54% | -19.23% | |
| Form 10-Q Zentalis Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | +4.80% | +12.00% | |
| Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress | Press release | +4.80% | +12.00% | |
| Form 10-Q Zentalis Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | -1.08% | +4.32% | |
| Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress | Press release | -1.08% | +4.32% | |
| Form 10-Q Zentalis Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | -2.42% | +1.61% | |
| Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress | Press release | -2.42% | +1.61% | |
| Form 10-K Zentalis Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | +6.99% | -3.76% | |
| Form 10-Q Zentalis Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | +4.66% | -3.92% | |
| Form 10-Q Zentalis Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | +9.33% | +0.00% | |
| Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress | Press release | +9.33% | +0.00% | |
| Form 10-Q Zentalis Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | -1.37% | -0.96% | |
| Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress | Press release | -1.37% | -0.96% | |
| Form 10-K Zentalis Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | +0.56% | +2.01% | |
| Form 10-Q Zentalis Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | -2.07% | -30.28% | |
| Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates | Press release | -2.07% | -30.28% |
Keep exploring
More ZNTL: analyst actions → · SEC filings → · ZNTL overview →